SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-), breast cancer patient who received neoadjuvant and adjuvant (Z)-endoxifen therapy under an FDA-approved 'expanded access' program has completed five years of treatment.

2024年3月19日，西雅图（环球通讯社）--Atossa Therapeutics，Inc.（纳斯达克：ATOS）（“Atossa”或“公司”）今天宣布，绝经前雌激素受体阳性（ER+）/人表皮生长因子受体2阴性（HER2-）的乳腺癌患者接受了新辅助和辅助治疗（Z）-根据FDA批准的“扩大获取”计划，endoxifen治疗已完成五年的治疗。

As of the date of this press release, the patient remains cancer-free and has reported no significant safety or tolerability issues over the course of her treatment. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.

截至本新闻稿发布之日，患者仍然没有癌症，并且在治疗过程中没有报告重大的安全性或耐受性问题。Atossa是一家临床阶段的生物制药公司，在肿瘤学领域的重大未满足医疗需求领域开发创新药物，重点是乳腺癌。

'We believe this patient, and her successful treatment journey, is representative of the opportunity (Z)-endoxifen has to change the treatment paradigm for the approximately 250,000 women diagnosed with estrogen receptor positive breast cancer each year in the U.S.,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer.

Atossa总裁兼首席执行官史蒂文·奎伊（StevenQuay）医学博士说：“我们相信这位患者及其成功的治疗历程代表了机会（Z）-endoxifen必须改变美国每年约25万名被诊断患有雌激素受体阳性乳腺癌的女性的治疗模式。”。

'The current standard of care is sub-optimal as it often requires ovarian suppression in premenopausal women and aromatase inhibitors in postmenopausal women, both of which are associated with potential short-term and long-term side effects that diminish adherence. Over five years of adjuvant treatment, her daily (Z)-endoxifen treatment has been well tolerated, and there were no vasomotor symptoms commonly associated with standard of care adjuvant pharmaceuticals.

“目前的护理标准是次优的，因为它通常需要绝经前妇女的卵巢抑制和绝经后妇女的芳香化酶抑制剂，这两者都与潜在的短期和长期副作用有关，从而减少依从性。经过五年的辅助治疗，她的每日（Z）-内昔芬治疗耐受性良好，并且没有通常与标准护理辅助药物相关的血管舒缩症状。

She remains cancer-free today and we are grateful to have been able to help her with a difficult treatment problem.” Patient / Treatment Background Diagnosis. In late 2018, a 51-year-old premenopausal woman was diagnosed with a.

她今天仍然没有癌症，我们很感激能够帮助她解决一个棘手的治疗问题。”患者/治疗背景诊断。2018年末，一名51岁的绝经前女性被诊断出患有a。